Second-generation antipsychotic injections for treating schizophrenia

Mental Health and Behaviour

1 October 2018

Published on 01 Oct 2018
Last Updated on 01 Oct 2018

Guidance Recommendations

The Ministry of Health’s Drug Advisory Committee has not recommended listing paliperidone or aripiprazole injections on the Medication Assistance Fund (MAF) for treating schizophrenia, due to unacceptable cost-effectiveness compared with first-generation antipsychotic injections at the prices proposed by the manufacturers.

SGA injections for schizophrenia (1 Oct 2018) [PDF, 44 KB]